Creative Medical Receives Exosome Diabetes Patent Allowance

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company, announced on August 6, 2026, that it received a Notice of Allowance from the United States — United States Patent and Trademark Office (USPTO) for a U.S. patent application titled 'Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells' (U.S. Application No. 17/931,868). The patent, once issued, will protect the company's MyeloCelz platform, a cell-free exosome technology designed to induce antigen-specific immune tolerance and suppress the autoimmune destruction of insulin-producing pancreatic beta cells in Type 1 diabetes. This allowance strengthens the company's intellectual property estate, which now includes approximately 60 issued patents and pending applications, with seven issued U.S. patents and 39 pending U.S. applications. The patent complements the company's diabetes portfolio, including CELZ-201 (olastrocel/AlloStem) in an FDA-cleared CREATE-1 trial, CELZ-101 (etaroleucel/ImmCelz) with FDA Orphan Drug Designation, and CELZ-001 for late-stage Type 2 diabetes. The company plans to complete formal issuance, advance clinical programs, and evaluate licensing and partnership opportunities. The global Type 1 diabetes market is estimated at roughly $18 billion in 2026, with significant unmet need for therapies inducing durable immune tolerance.